Convidecia Air® (XBB.1.5 Variant)
COVID-19 Prevention
ApprovedMarketed
Key Facts
About CanSino Biologics
A leading Chinese vaccine developer leveraging adenovirus vector technology to create innovative vaccines for global infectious disease prevention.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| Replicon RNA COVID-19 Vaccine | BIKEN Group | Preclinical/Development |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |